Jimma Lenjisa Home Page, University of South Australia

Research

Research focus

Medicinal and Biomolecular Chemistry
Oncology and Carcinogenesis
Organic Chemistry
Pharmacology and Pharmaceutical Sciences
Paediatrics and Reproductive Medicine

Research

Outputs

Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID or Scopus

Open access indicates that an output is open access.

Journal Articles

Year	Output
2024	Kasirzadeh, S, Lenjisa, JL & Wang, S 2024, 'Targeting CDK2 to combat drug resistance in cancer therapy', Future Oncology, online, pp. 1-17.
2023	Fanta, BS, Mekonnen, L, Basnet, SK, Teo, T, Lenjisa, J, Khair, NZ, Kou, L, Tadesse, S, Sykes, MJ, Yu, M & Wang, S 2023, '2-Anilino-4-(1-methyl-1H-pyrazol-4-yl)pyrimidine-derived CDK2 inhibitors as anticancer agents: design, synthesis & evaluation', Bioorganic and Medicinal Chemistry, vol. 80, article no. 117158, pp. 1-15. 11 11 1
2023	Safaroghli-Azar, A, Emadi, F, Lenjisa, J, Mekonnen, L & Wang, S 2023, 'Kinase inhibitors: opportunities for small molecule anticancer immunotherapies', Drug Discovery Today, vol. 28, no. 5, pp. 1-12. 1 2
2023	Sintayehu Fanta, B, Lenjisa, J, Teo, T, Kou, L, Mekonnen, L, Yang, Y, Basnet, SK, Hassankhani, R, Sykes, MJ, Yu, M & Wang, S 2023, 'Discovery of N,4-Di(1H-pyrazol-4-yl)pyrimidin-2-amine-derived CDK2 inhibitors as potential anticancer agents: design, synthesis, and evaluation', Molecules, vol. 28, no. 7, article no. 2951, pp. 1-21. Open access 3 3 2
2022	Anshabo, AT, Bantie, L, Diab, S, Lenjisa, J, Kebede, A, Long, Y, Heinemann, G, Karanjia, J, Noll, B, Basnet, SK, Li, M, Milne, R, Albrecht, H & Wang, S 2022, 'An orally bioavailable and highly efficacious inhibitor of CDK9/FLT3 for the treatment of acute myeloid leukemia', Cancers, vol. 14, no. 5, article no. 1113, pp. 1-19. Open access 9 8 23
2020	Bantie, L, Tadesse, S, Likisa, J, Yu, M, Noll, B, Heinemann, G, Lokman, NA, Ricciardelli, C, Oehler, MK, Beck, A, Pradhan, R, Milne, R, Albrecht, H & Wang, S 2020, 'A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer', Gynecologic Oncology, vol. 159, no. 3, pp. 827-838. 10 13 1

External engagement & recognition

Collaborations

External engagement & recognition

Collaborations

Organisation	Country
University of Adelaide	AUSTRALIA
University of South Australia	AUSTRALIA

Teaching & student supervision

Research degree supervision

Supervisions from 2010 shown

Thesis title	Student status
CDK inhibitors as immunotherapeutic agents for cancer treatment	Current
Development of Cyclin Dependent Kinase Inhibitors for Cancer Treatment	Current

Dr Jimma Lenjisa

About me

About me

UniSA Clinical & Health Sciences

About me

Professional Associations

Experience

Qualifications

Research

Research focus

Projects

Outputs

Journal Articles

External engagement & recognition

Collaborations

Collaborations

Teaching & student supervision

Courses and programs

Courses I teach

Research degree supervision

Gallery